# Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension

Study · id `cardio:ct-nct07932145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07932145](<https://clinicaltrials.gov/study/NCT07932145>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07932145

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 128 participants.

## Technical summary

Registry record NCT07932145. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT07932145, source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07932145, source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07932145, source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-04-30 (anticipated) (ClinicalTrials.gov record NCT07932145, source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07932145, source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07932145-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension
- Acronym: EMERALD
- Condition: Hypertension (HTN)
- Condition: Low-Renin Essential Hypertension
- Intervention (Drug): Eplerenone
- Intervention (Drug): Telmisartan
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Telmisartan (`cardio:telmisartan`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 9ac62d7cba2b05e4860400b2ac2f10dcd8ca5421572259188cfb1790f5da8afb
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
